Zacks Investment Research | May 02, 2018 10:27PM ET
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported a loss of 15 cents per share for the first quarter of 2018, same as the year-ago loss but wider than the Zacks Consensus Estimate of a loss of 14 cents.
The company generated no revenues in the reported quarter.
Shares of Achillion were down 2.4% on May 2. However, the company's stock have outperformed the industry year to date. The company’s shares have gained 28.1% against the industry’s decrease of 10.9%.
Research and development (R&D) expenses decreased nearly 4.8% from the year-ago period to $14.6 million. The decrease was due to decreased stock-based compensation, lower personnel costs as the February restructuring resulted in reduced number of employees and lower manufacturing and formulation expenses for next generation factor D inhibitor candidate, ACH-5228. This was partially offset by increased costs related to clinical studies of ACH-4471 and ACH-5228 and preclinical costs of ACH-5548.
General and administrative (G&A) expenses decreased 5.9% year over year to $5.3 million due to lower legal and consulting fees.
Restructuring Details
In February 2018, the company announced an operational restructuring plan to focus on its existing factor D inhibitor candidates and reduce expenses. Achillion reduced its workforce by 20% under its restructuring plan. The restructuring is expected to save $10 million in 2018.
Pipeline Update
Achillion is planning to complete a phase II study on its most advanced candidate, ACH-4471, in C3 glomerulopathy (C3G) or immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) in 2018, with interim data planned for the third quarter of 2018. Two more studies are planned for 2018, which will evaluate ACH-4471 in C3G.
Meanwhile, interim data from the ongoing phase II study evaluating ACH-4471 monotherapy in paroxysmal nocturnal hemoglobinuria (“PNH”) is planned for the fourth quarter of 2018. An add-on study is planned for the evaluation of ACH-4471 in combination with Alexion Pharmaceuticals’ (NASDAQ:ALXN) PNH drug, Soliris (eculizumab). Interim data is expected in the fourth quarter of 2018.
The company also targets to complete phase I studies on its two next generation factor D inhibitors – ACH-5228 and ACH-5548 – in the fourth quarter of 2018.
CEO Transition
Concurrent with the earnings release, Achillion announced that Joseph Truitt, current president and chief operating officer, will take the responsibilities of chief executive officer. Milind Deshpande is stepping down from this role. Joseph will also be appointed to the board of directors.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.